Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Next Previous
X
Search
Trial Profile

A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ChAdV68 S (Primary) ; ChAdV68 S TCE (Primary) ; SAM LNP S (Primary) ; SAM LNP S TCE (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Proof of concept
  • Acronyms CORAL-NIH

    • Most Recent Events

    • 19 Oct 2023 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2023 Results published in the Gritstone Oncology Media Release
    • 04 Oct 2023 According to a Gritstone bio media release, data from this study will be presented at the IDWeek 2023, occurring October 11-15, 2023, in Boston, MA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top